Jump to content

BFAI

Edit links
From Wikipedia, the free encyclopedia
BFAI
Clinical data
Other names5,6-Benzofuranyl-2-aminoindane; 5,6-Benzofuranyl-2-aminoindan
Drug classSelective serotonin releasing agent; Entactogen
ATC code
  • None
Identifiers
  • 6,7-dihydro-5H-cyclopenta[f][1]benzofuran-6-amine
CAS Number
PubChem CID
Chemical and physical data
FormulaC11H11NO
Molar mass173.215 g·mol−1
3D model (JSmol)
  • C1C(CC2=C1C=C3C=COC3=C2)N
  • InChI=1S/C11H11NO/c12-10-4-8-3-7-1-2-13-11(7)6-9(8)5-10/h1-3,6,10H,4-5,12H2
  • Key:SYCRQDBZPIEBIR-UHFFFAOYSA-N

BFAI, also known as 5,6-benzofuranyl-2-aminoindane, is a drug of the 2-aminoindane family that acts as a serotonin releasing agent (SSRA) and may produce entactogenic effects in humans, which may be useful for psychotherapeutic applications. It is closely related to MDAI but with the benzodioxole ring system replaced by benzofuran.[1] The drug was patented by Matthew Baggott and Tactogen in 2022.[1]

See also

[edit]

References

[edit]
  1. ^ a b WO 2022/032147, Baggott M, "2-Aminoindane compounds for mental disorders or enhancement.", published 10 February 2022, assigned to Tactogen Inc. 
[edit]
Stub icon

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=BFAI&oldid=1322829570"